Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma

被引:4
|
作者
Rafael S. Rios
Kenneth I. Zheng
Ming-Hua Zheng
机构
[1] China
[2] Department of Hepatology
[3] NAFLD Research Center
[4] Zhejiang 325000
[5] the First Affiliated Hospital of Wenzhou Medical University
基金
中国国家自然科学基金;
关键词
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Liver disease; Hepatocellular carcinoma; Insulin resistance; Oxidative stress; Metabolic associated fatty liver disease;
D O I
暂无
中图分类号
R735.7 [肝肿瘤]; R575.5 [肝代谢障碍];
学科分类号
1002 ; 100201 ; 100214 ;
摘要
The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.
引用
收藏
页码:2911 / 2921
页数:11
相关论文
共 50 条
  • [31] HEPATOCELLULAR CARCINOMA AND NON-ALCOHOLIC FATTY LIVER DISEASE: A DANGEROUS LIAISON
    Nevola, R.
    Acierno, C.
    Sasso, F. C.
    Marrone, A.
    Buffardi, F.
    Adinolfi, L. E.
    Rinaldi, L.
    WORLD CANCER RESEARCH JOURNAL, 2019, 6
  • [32] Non-alcoholic fatty liver disease and hepatocellular carcinoma-2016
    Par Alajos
    Par Gabriella
    ORVOSI HETILAP, 2016, 157 (25) : 987 - 994
  • [33] Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment
    Argyrou, Chrysoula
    Moris, Demetrios
    Vemadakis, Spiridon
    JOURNAL OF BUON, 2017, 22 (01): : 6 - 20
  • [34] Hepatocellular carcinoma and non-alcoholic fatty liver disease
    Pegah Golabi
    Logan Rhea
    Linda Henry
    Zobair M. Younossi
    Hepatology International, 2019, 13 : 688 - 694
  • [35] Liver fibrogenesis in non-alcoholic steatohepatitis
    Bian, Zhaolian
    Ma, Xiong
    FRONTIERS IN PHYSIOLOGY, 2012, 3
  • [36] Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis
    Maeda, Takashi
    Hashimoto, Koji
    Kihara, Yuki
    Ikegami, Toru
    Ishida, Teruyoshi
    Aimitsu, Shiomi
    Fujiwara, Megumu
    HEPATO-GASTROENTEROLOGY, 2008, 55 (85) : 1404 - 1406
  • [37] Emerging drugs for non-alcoholic steatohepatitis
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Ogawa, Yuji
    Kessoku, Takaomi
    Saito, Satoru
    Eguchi, Yuichiro
    Nakajima, Atsushi
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) : 279 - 290
  • [38] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [39] Role of microRNAs in Non-Alcoholic Steatohepatitis
    Cheung, Onpan
    Sanyal, Arun J.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1952 - 1957
  • [40] Non-alcoholic steatohepatitis and metabolic syndrome
    Machado, Mariana
    Cortez-Pinto, Helena
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2006, 9 (05) : 637 - 642